ALX Oncology Doses First Patient In Phase 2 ASPEN-09-Breast Trial Evaluating Its Investigational CD47-Inhibitor Evorpacept.

- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician's choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 –

- Third dose cohort initiated in Phase 1 trial of ALX 2004; study remains on track to provide initial safety data in 1H 2026 -